US2022000812A1PendingUtilityA1

Methods and compositions for treating conditions associated with an abnormal inflammatory responses

Assignee: FIRST WAVE BIO INCPriority: Sep 1, 2015Filed: Feb 8, 2021Published: Jan 6, 2022
Est. expirySep 1, 2035(~9.1 yrs left)· nominal 20-yr term from priority
A61P 1/04A61P 29/00A61K 9/1635A61K 9/0031A61P 17/06A61K 9/10A61K 31/167A61K 45/06A61P 43/00A61K 47/38A61P 1/00A61K 47/32A61P 19/02A61P 37/06A61P 27/02A61P 17/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for inducing cell death of one or more T cells in the gastrointestinal tract (GI) of a subject, the method comprising contacting the one or more T cells with an effective amount of a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate thereof.

Join the waitlist — get patent alerts

Track US2022000812A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.